The MedicalXpress coverage accurately outlines Vertex's VX-880 trial (n=12, open-label phase 1/2, 83% insulin independence at six months) and the single-patient Chinese iPSC case achieving 12-month independence, yet underplays critical gaps in durability data and trial design quality. Both represent small, non-randomized case series prone to selection bias rather than rigorous RCTs; no peer-reviewed long-term follow-up beyond one year exists, and conflicts of interest at Vertex (public company with $3B+ market cap tied to success) warrant scrutiny. Synthesizing with the 2022 NEJM VX-880 report and a 2024 Nature Reviews Endocrinology analysis of 15 global trials (total n<100), the field shows consistent short-term C-peptide restoration but highlights autoimmune recurrence risks unaddressed by autologous iPSCs alone. Original reporting misses economic modeling: scaling GMP-grade cells to treat 8.4 million global type 1 cases could cost $250B initially, per Health Affairs projections, while hypoimmunogenic gene-edited lines (e.g., CRISPR HLA-knockout approaches) remain preclinical. Patterns from prior regenerative efforts, like CAR-T oncology scaling, suggest 5-7 years before broad access, positioning this as transformative only if immune-shielding capsules advance beyond animal models.